MarketPulse

Mucopolysaccharidosis Type I

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gene Therapy Giant REGENXBIO Faces Class Action Over RGX-111 Misstatements

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy. Covers investors from Feb 2022 to Jan 2026; lead plaintiff deadline April 14.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Targets REGENXBIO Over Gene Therapy Claims

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.
RGNXsecurities fraudclass action lawsuit